From: MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Radiologic response
MGMT
Negative
Positive
Unmethylated
33 (82.5%)
7 (17.5%)
Methylated
17 (56.7%)
13 (43.3%)
Total
50 (71.4%)
20 (28.6%)